1h Free Analyst Time
The global stem cell umbilical cord blood (ucb) market is forecasted to grow by USD 2.16 billion during 2025-2030, accelerating at a CAGR of 17.9% during the forecast period. The report on the global stem cell umbilical cord blood (ucb) market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.Speak directly to the analyst to clarify any post sales queries you may have.
The report offers an up-to-date analysis regarding the current market scenario, the latest trends and drivers, and the overall market environment. The market is driven by rising prevalence of hematological disorders and chronic diseases, expansion of regenerative medicine applications, advancements in banking infrastructure and preservation technologies.
The study identifies the emergence and adoption of hybrid and community banking models as one of the prime reasons driving the global stem cell umbilical cord blood (ucb) market growth during the next few years. Also, expansion of clinical indications beyond traditional hematopoietic reconstitution and integration of automated processing and cryopreservation technologies will lead to sizable demand in the market.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market size data, segment with regional analysis and vendor landscape in addition to an analysis of the key companies. Reports have historic and forecast data.
The global stem cell umbilical cord blood (ucb) market is segmented as below:
By End-User
- Pharmaceutical
- Research institutes
- Hospitals
- Biobanks
By Type
- Private UCB
- Public UCB
By Application
- Leukemia
- Bone marrow failure syndrome
- Metabolic disorders
- Others
By Region
- North America
- Asia
- Europe
- Rest of World (RoW)
- Rest of World (RoW)
The report covers the following areas:
- Global stem cell umbilical cord blood (ucb) market sizing
- Global stem cell umbilical cord blood (ucb) market forecast
- Global stem cell umbilical cord blood (ucb) market industry analysis
The report presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive primary and secondary research. The market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast accurate market growth.
Table of Contents
1 Executive Summary
2 Market Analysis
3 Market Landscape
4 Market Sizing
5 Historic Market Size
6 Qualitative Analysis
7 Five Forces Analysis
8 Market Segmentation by End-user
9 Market Segmentation by Type
10 Market Segmentation by Application
11 Customer Landscape
12 Geographic Landscape
13 Drivers, Challenges, and Opportunity
14 Competitive Landscape
15 Competitive Analysis
16 Appendix
List of Exhibits
Executive Summary
The following companies are recognized as the key players in the global global stem cell umbilical cord blood (ucb) market: Americord Registry LLC, Athersys Inc., CBR Systems Inc., Cells4Life Group LLP, Celularity Inc., Cordlife Group Ltd., Cryo Cell International Inc., Cryoviva Biotech Pvt. Ltd., FamiCord Group, FUTURE CELL JAPAN, Global Cord Blood Corp., LifeCell International Pvt. Ltd., MEDIPOST Co. Ltd., Next Biosciences Pty Ltd., Regrow Biosciences Pvt Ltd., Smart Cells International Ltd., Smith and Nephew plc, STEMCELL Technologies Inc., ViaCord LLC, Vita 34 AG.Commenting on the report, an analyst from the research team said: "The latest trend gaining momentum in the market is emergence and adoption of hybrid and community banking models."
According to the report, one of the major drivers for this market is the rising prevalence of hematological disorders and chronic diseases.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Americord Registry LLC
- Athersys Inc.
- CBR Systems Inc.
- Cells4Life Group LLP
- Celularity Inc.
- Cordlife Group Ltd.
- Cryo Cell International Inc.
- Cryoviva Biotech Pvt. Ltd.
- FamiCord Group
- FUTURE CELL JAPAN
- Global Cord Blood Corp.
- LifeCell International Pvt. Ltd.
- MEDIPOST Co. Ltd.
- Next Biosciences Pty Ltd.
- Regrow Biosciences Pvt Ltd.
- Smart Cells International Ltd.
- Smith and Nephew PLC
- STEMCELL Technologies Inc.
- ViaCord LLC
- Vita 34 AG
